Wall Street brokerages expect Mesoblast limited (NASDAQ:MESO) to report sales of $2.51 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Mesoblast’s earnings, with the highest sales estimate coming in at $4.00 million and the lowest estimate coming in at $1.01 million. Mesoblast reported sales of $570,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 340.4%. The firm is scheduled to report its next quarterly earnings report on Tuesday, September 4th.
According to Zacks, analysts expect that Mesoblast will report full-year sales of $17.52 million for the current fiscal year, with estimates ranging from $16.65 million to $19.00 million. For the next financial year, analysts forecast that the business will post sales of $9.39 million per share, with estimates ranging from $6.38 million to $15.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Mesoblast.
Mesoblast (NASDAQ:MESO) last posted its quarterly earnings data on Thursday, May 31st. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.02). The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $0.35 million. Mesoblast had a negative return on equity of 11.77% and a negative net margin of 256.91%.
Several research analysts have recently weighed in on MESO shares. HC Wainwright started coverage on Mesoblast in a research report on Thursday, June 7th. They set a “buy” rating and a $17.00 price objective for the company. Cantor Fitzgerald set a $23.00 target price on Mesoblast and gave the stock a “buy” rating in a report on Thursday, May 31st. Zacks Investment Research upgraded Mesoblast from a “sell” rating to a “hold” rating in a report on Wednesday, August 1st. Maxim Group upped their target price on Mesoblast from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, July 18th. Finally, ValuEngine upgraded Mesoblast from a “sell” rating to a “hold” rating in a report on Thursday, July 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. Mesoblast presently has an average rating of “Buy” and an average price target of $14.32.
A hedge fund recently raised its stake in Mesoblast stock. Princeton Capital Management LLC increased its stake in shares of Mesoblast limited (NASDAQ:MESO) by 18.8% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 147,293 shares of the company’s stock after acquiring an additional 23,271 shares during the period. Princeton Capital Management LLC owned about 0.16% of Mesoblast worth $851,000 as of its most recent filing with the SEC. 2.92% of the stock is owned by institutional investors.
Shares of Mesoblast remained flat at $$6.30 on Friday, MarketBeat.com reports. The stock had a trading volume of 38,297 shares, compared to its average volume of 102,020. The company has a quick ratio of 3.46, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $593.28 million, a PE ratio of -6.49 and a beta of 2.14. Mesoblast has a 52 week low of $4.74 and a 52 week high of $7.79.
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions.
Read More: Trading Strategy Examples and Plans
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.